Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci

Bente Glintborg; Anne Gitte Loft; Emina Omerovic; Oliver Hendricks; Asta Linauskas; Jakob Espesen; Kamilla Danebod; Dorte Vendelbo Jensen; Henrik Nordin; Emil Barner Dalgaard; Stavros Chrysidis; Salome Kristensen; Johnny Lillelund Raun; Hanne Lindegaard; Natalia Manilo; Susanne Højmark Jakobsen; Inger Marie Jensen Hansen; Dorte Dalsgaard Pedersen; Inge Juul Sørensen; Lis Smedegaard Andersen; Jolanta Grydehøj; Frank Mehnert; Niels Steen Krogh; Merete Lund Hetland

doi:10.1136/annrheumdis-2018-214788

Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB₄: possible fallout on non-medical switching' by Cantini and Benucci

Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.

Authors

Bente Glintborg^{1

2}, Anne Gitte Loft^{3

4}, Emina Omerovic⁵, Oliver Hendricks⁶, Asta Linauskas⁷, Jakob Espesen⁸, Kamilla Danebod², Dorte Vendelbo Jensen², Henrik Nordin⁹, Emil Barner Dalgaard¹⁰, Stavros Chrysidis¹¹, Salome Kristensen¹², Johnny Lillelund Raun¹³, Hanne Lindegaard¹⁴, Natalia Manilo¹⁵, Susanne Højmark Jakobsen¹⁶, Inger Marie Jensen Hansen¹⁶, Dorte Dalsgaard Pedersen¹⁶, Inge Juul Sørensen¹⁷, Lis Smedegaard Andersen¹⁸, Jolanta Grydehøj¹⁹, Frank Mehnert²⁰, Niels Steen Krogh²¹, Merete Lund Hetland^{22

17}

Affiliations

¹ The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark [email protected].
² Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
³ Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁵ Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, København, Denmark.
⁶ Kong Christian X's Gigthospital, Gråsten, Denmark.
⁷ Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark.
⁸ Department of Rheumatology, Vejle Hospital, Vejle, Denmark.
⁹ Department of Rheumatology, Zealand University Hospital, Køge, Denmark.
¹⁰ Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark.
¹¹ Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark.
¹² Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
¹³ Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark.
¹⁴ Department of Rheumatology, Odense University Hospital, Odense, Denmark.
¹⁵ Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark.
¹⁶ Department of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark.
¹⁷ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
¹⁸ Department of Internal Medicine, Rønne Hospital, Rønne, Denmark.
¹⁹ Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark.
²⁰ Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
²¹ Zitelab, Copenhagen, Denmark.
²² The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark.

PMID: 30573653
DOI: 10.1136/annrheumdis-2018-214788

No abstract available

Keywords: DMARDs (biologic); anti-tnf; epidemiology; outcomes research.

Publication types

Letter
Comment

MeSH terms

Antirheumatic Agents*
Biosimilar Pharmaceuticals*
Etanercept
Humans
Registries
Treatment Outcome

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Etanercept